CDKN2B and leukemia: The growth advantage of NFKBIE-ko cells in response to stimulation with the TLR ligands CpG and LPS was further validated in independent experiments with another TCL1 leukemia line with combined TP53, CDKN2A and CDKN2B disruption (Supplementary Fig. 3) [19].